

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/622,725	07/18/2003	Frank Butaric	CRD-0836 DIV 1	2936
27777	7590 11/09/2006		EXAMINER	
PHILIP S. JOHNSON			MILLER, CHERYL L	
JOHNSON & JOHNSON ONE JOHNSON & JOHNSON PLAZA		ART UNIT	PAPER NUMBER	
NEW BRUNS	NEW BRUNSWICK, NJ 08933-7003			
	•		DATE MAILED: 11/09/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

DETAILED ACTION

Response to Arguments

Applicant's arguments with respect to claims 1-6 have been considered but are moot in view of the new ground(s) of rejection.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-4 are rejected under 35 U.S.C. 102(b) as being anticipated by Lunn (US 5,476,506, cited previously). Lunn discloses a stent graft (fig. 1, 4, 5) comprising a hollow cylindrical radially expandable stent (36, 38, 50, or 52) having a body, two open ends and a longitudinal axis, the body comprising a plurality of interconnected struts (as seen in figs.5a-5d) forming a plurality of diamond shaped cells and a plurality of sinusoidal rings positioned between the cells (see attachment 1), and a graft member (10) attached to the body of the stent, the graft (10) having a plurality of longitudinally directed pleats (22+24). Lunn discloses the graft (10) attached to the exterior of the stent (36, 38, 50, 52). Lunn discloses a graft (10) made of the materials claimed (col.5, lines 59-67). Lunn discloses the graft (10) attached to the stent (36, 38, 50, or 52) by a staple (col.5, lines 10-14).

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

Art Unit: 3738

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 5-6 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lunn (US 5,476,506, cited previously). Lunn discloses a stent graft substantially as claimed. Lunn however, discloses a balloon expandable stent instead of a self expanding stent. It would have been obvious to one having ordinary skill in the art at the time the invention was made to have a nitinol or such type of self expanding stent, since self expanding stent materials are know alternatives to balloon expandable stent materials, and also since it has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use as a matter of obvious design choice. *In re Leshin*, 125 USPQ 416.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 3738

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cheryl Miller whose telephone number is (571) 272-4755. The examiner can normally be reached on Monday-Friday 7:30am-5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Corrine McDermott can be reached on (571) 272-4755. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Cheryl Miller

infullle

BRUCE SNOW PRIMARY EXAMINER

achment #1 (marked up) 5,476,506 U.S. Patent Dec. 19, 1995 Sheet 3 of 4 52 20 ġ FIG.5A FIG. 5B